Welcome to the Wnt & β-Catenin Targeted Drug Discovery Summit

Returning for its for 2nd edition, the Wnt/B-Catenin Targeted Drug Development Summit will host the leaders from Academia, Pharma and Biotech’s, to focus on driving translational research and drug development for Wnt/β-Catenin Candidates.

After 2 decades of research, it is now the time for drug developers to act and get together at the 2nd Wnt/β-Catenin Pathway Targeted Drug Development Summit. As the one and only industry-led meeting, you hear all the latest insights in topics from looking at structural biology and modulation approaches, through to validating clinical biomarkers and reducing toxicity.

If you’re working in the Wnt/B-Catenin or IO space, or want to learn more about its potential for drug development, this is your chance to ask questions to the experts in the field, network with 80+ industry players, and gain invaluable insights to take you in 2023 and beyond.

What you will learn:

logo square

The best therapeutic strategies for targeting the Wnt/B-Catenin Pathway

logo square

Intracellular methods for targeting Wnt downstream

logo square

Different inhibitor approaches to block Wnt/B-Catenin Signalling

logo square

Looking at improving our immune-oncology understanding of Wnt Pathways and Immune Cells

logo square

How to overcome or preempt safety and scheduling challenges

logo square

Learning the newest clinical updates from the industry

Who you will meet:

logo square

Academics

logo square

Bio-Techs

logo square

Pharmaceutical Companies

2021's Expert Speakers Included

Gary A. Piazza

Department Head, Drug Discovery & Development

Auburn University

Stephen Horrigan

Chief Scientific Officer

Iterion Therapeutics

Caroline Phillips

Head of Oncology

Redx Pharma

Greg Verdine

President, CEO and CSO

Fog Pharma

Kelly Mercier

Chair

Desmoid Tumors Research Foundation Coordinating Center

Mike Kagey

Senior Director of Translational Medicine

Leap Therapeutics

Rami N. Hannoush

Senior Principal Scientist and Group Leader, Early Discovery Biochemistry

Genentech

Trudy Vanhove

Chief Medical Officer

Surrozen